title: Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study.
abstract: Memantine is an N-methyl-D: -aspartate (NMDA) receptor antagonist, approved for the treatment of moderate to severe Alzheimer's disease (AD). We conducted a 4-month observational, post-marketing, Austrian study of memantine in 377 outpatients with moderate to severe AD. In this 'real-life' setting, memantine was well-tolerated, and produced benefits in cognition (Mini-Mental State Examination), activities of daily living (Activities of Daily Living score), and global function (Clinical Global Impression scale). Treatment effects were apparent in both pre-treated and treatment-naïve patient subgroups.
authors: Memory Clinic and Psychiatric Department, Donauspital Sozialmedizinisches Zentrum Ost, Langobardenstrasse 122, 1220, Wien, Austria. Michael.Rainer@wienkav.at
authors: Michael
authors: M
authors: Rainer
authors: A
authors: A
authors: Wuschitz
authors: C
authors: C
authors: Jagsch
authors: C
authors: C
authors: Erb
authors: J-J
authors: JJ
authors: Chirikdjian
authors: H A M
authors: HA
authors: Mucke
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology*; D005260:Female; D006801:Humans; D008297:Male; D008559:Memantine / Q000627:therapeutic use*; D011358:Product Surveillance, Postmarketing / Q000379:methods*; D011446:Prospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D008559:Memantine